Clinical potential of eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome

被引：16

作者：

Sobolewska-Wlodarczyk, Aleksandra ^{[1
]}

Wlodarczyk, Marcin ^{[1
]}

Storr, Martin ^{[2
]}

Fichna, Jakub ^{[1
]}

机构：

[1] Med Univ Lodz, Fac Med, Dept Biochem, Mazowiecka 6-8, PL-92215 Lodz, Poland

[2] Ctr Endoscopy, Starnberg, Germany

来源：

THERAPEUTICS AND CLINICAL RISK MANAGEMENT | 2016年 / 12卷

关键词：

abdominal pain; health care; functional gastrointestinal disorders; IBS; constipation; discomfort; DELTA-OPIOID RECEPTOR; CONSTIPATION; MANAGEMENT; DISORDERS;

D O I：

10.2147/TCRM.S83722

中图分类号：

R19 [保健组织与事业（卫生事业管理）];

学科分类号：

摘要：

Diarrhea-predominant irritable bowel syndrome (IBS-D) belongs to the group of functional gastrointestinal disorders and is characterized by abdominal pain in conjunction with diarrhea. The incidence of IBS-D is currently increasing, leading to a heavy economic burden for patients and health care systems worldwide. Recent studies suggest eluxadoline as an attractive new tool for the treatment of patients with IBS-D. Eluxadoline is an orally active mu- and kappa-opioid receptor agonist and delta-opioid receptor antagonist, with powerful antidiarrheal and analgesic activity. Eluxadoline is believed to act locally in the enteric nervous system, and has no adverse effects in the central nervous system. In this review, we discuss the most recent findings on the mechanism of action of eluxadoline and the results of the clinical trials in patients with IBS-D. We also discuss possible side effects and analyze the potential of eluxadoline to be used in the treatment of IBS-D.

引用

页码：771 / 775

页数：5

共 28 条

[1]

Andrae D, 2015, GASTROENTEROLOGY, V148, pS494

[2] An Evidence-Based Position Statement on the Management of Irritable Bowel Syndrome [J].

Brandt, Lawrence J. ;

Chey, William D. ;

Foxx-Orenstein, Amy E. ;

Quigley, Eamonn M. M. ;

Schiller, Lawrence R. ;

Schoenfeld, Philip S. ;

Spiegel, Brennan M. ;

Talley, Nicholas J. ;

Moayyedi, Paul .

AMERICAN JOURNAL OF GASTROENTEROLOGY, 2009, 104 :S1-S36

[3]

Chey WD, 2015, GASTROENTEROLOGY, V148, pS70

[4] Irritable Bowel Syndrome A Clinical Review [J].

Chey, William D. ;

Kurlander, Jacob ;

Eswaran, Shanti .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2015, 313 (09) :949-958

[5] Nerve Fiber Outgrowth Is Increased in the Intestinal Mucosa of Patients With Irritable Bowel Syndrome [J].

Dothel, Giovanni ;

Barbaro, Maria Raffaella ;

Boudin, Helene ;

Vasina, Valentina ;

Cremon, Cesare ;

Gargano, Luciana ;

Bellacosa, Lara ;

De Giorgio, Roberto ;

Le Berre-Scoul, Catherine ;

Aubert, Philippe ;

Neunlist, Michel ;

De Ponti, Fabrizio ;

Stanghellini, Vincenzo ;

Barbara, Giovanni .

GASTROENTEROLOGY, 2015, 148 (05) :1002-U456

[6] Eluxadoline Benefits Patients With Irritable Bowel Syndrome With Diarrhea in a Phase 2 Study [J].

Dove, Leonard S. ;

Lembo, Anthony ;

Randall, Charles W. ;

Fogel, Ronald ;

Andrae, David ;

Davenport, J. Michael ;

McIntyre, Gail ;

Almenoff, June S. ;

Covington, Paul S. .

GASTROENTEROLOGY, 2013, 145 (02) :329-+

[7]

Fass Ronnie, 2009, Gastrointest Endosc Clin N Am, V19, P23, DOI 10.1016/j.giec.2008.12.002

[8] American College of Gastroenterology Monograph on the Management of Irritable Bowel Syndrome and Chronic Idiopathic Constipation [J].

Ford, Alexander C. ;

Moayyedi, Paul ;

Lacy, Brian E. ;

Lembo, Anthony J. ;

Saito, Yuri A. ;

Schiller, Lawrence R. ;

Soffer, Edy E. ;

Spiegel, Brennan M. R. ;

Quigley, Eamonn M. M. .

AMERICAN JOURNAL OF GASTROENTEROLOGY, 2014, 109 :S2-S26

[9] Molecular characterization of eluxadoline as a potential ligand targeting mu-delta opioid receptor heteromers [J].

Fujita, Wakako ;

Gomes, Ivone ;

Dove, Leonard S. ;

Prohaska, David ;

McIntyre, Gail ;

Devi, Lakshmi A. .

BIOCHEMICAL PHARMACOLOGY, 2014, 92 (03) :448-456

[10]

Gebhart GF, 2000, ANN NY ACAD SCI, V909, P41

← 1 2 3 →